sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Inclusion Criteria: * Patients must have a pathologically confirmed diagnosis of prostate adenocarcinoma * Patients must have metastatic (M1) disease as evidenced by soft tissue and/or bony metastases on computed tomography (CT) or magnetic resonance imaging (MRI) scan or technetium bone scan * Patients must have castration resistant disease with disease progression despite castrate levels of testosterone (testosterone =\< 50 ng/dL) * Patients must have received and progressed on at least one second generation androgen receptor (AR) targeted therapy for castration resistant disease irrespective of prior chemotherapy. No more than 3 prior treatment therapies for castration resistant disease (life prolonging) are permitted. Prior therapy can include: * Second generation AR targeted therapy (i.e. abiraterone, enzalutamide, or other new antiandrogen \[ODM-201, apalutamide\]) * Chemotherapy (docetaxel and/or cabazitaxel) * Documented progressive mCRPC based on at least one of the following criteria: * PSA progression defined as 25% increase over baseline value with an increase in the absolute value of at least 2.0 ng/mL that is confirmed by another PSA level with a minimum of a 1 week interval and a minimum PSA of 2.0 ng/mL * Progression of bi-dimensionally measurable soft tissue or nodal metastasis assessed within one month prior to registration by a CT scan or MRI * Progression of bone disease (evaluable disease) (new bone lesion\[s\]) by bone scan * Serum testoster…